Hematological and Clinical Profile of BCR-ABL Confirmed Chronic Myeloid Leukemia Patients at Presentation in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia
| dc.contributor.advisor | Urgessa Fekadu | |
| dc.contributor.advisor | Tsegaye Aster | |
| dc.contributor.advisor | Gebremedhin Amha | |
| dc.contributor.advisor | Abdella Fozia | |
| dc.contributor.author | Lengiso Boki | |
| dc.date.accessioned | 2025-08-13T07:53:07Z | |
| dc.date.available | 2025-08-13T07:53:07Z | |
| dc.date.issued | 2023-12 | |
| dc.description.abstract | Background: Chronic Myeloid Leukemia (CML) is a risk of morbidity and death across the worldparticularly in low-income countries, due to late detection, poor adherence and its impact on youthpopulation. However, there is scarcity of evidence in hematological and clinical profile in newlyconfirmed CML patients in Ethiopia. Thus, we aimed to investigate the hematological and clinicalprofile of BCR-ABL confirmed Chronic Myeloid Leukemia patients during presentation at TikurAnbesa Specialized Hospital. Objective: To determine the Hematological and clinical profile of BCR-ABL confirmed ChronicMyeloid Leukemia patients during presentation at Tikur Anbesa Specialized Hospital. Methods: A facility-based cross-sectional study was conducted to address hematological andClinical Profile among new BCR-ABL confirmed patients at Tikur Anbesa Specialized Hospital(TASH) from August 2021 to December 2022. Convenient sampling technique was used and 256patients were included. Structured questionnaire was used to collect the patients’ socio-demographic, medical history and physical examination. About 5ml of blood sample was collectedfor hematological profile test. The laboratory analysis was conducted by using Unicel DxH800analyzer at TASH. Data was entered to Microsoft excel database and analyzed by statisticalsoftware for social science version 26. Descriptive statistics was used to explain socio-demographic, Hematological and clinical profile of study participants. A P-value of <0.05 were considered as statistically significant. Result: A total of 256 patients diagnosed with CML were identified. The majority (59.8 %) weremale and the median age was 36 years. The distribution of CML phase among the participants was,217 (84.78%) were in chronic phase, 31 (12.1 %) were in accelerated phase and 8 (3.1 %) patients were in Blast Crisis. Among the participants who were naïve to the Pre-chemo treatments, themedian and IQR values for WBC, RBC, HGB and PLT counts were 262.7(190.5-352.1) x103/μL,3.0(2.6-3.6) x106/μL, 8.8(7.9-10.1) g/dl and 320(209.5-449.8) x103/μL, respectively. All patientsexhibited Leukocytosis, with about 93.3% of them experiencing hyperleukocytosis. Additionally,among the study participants, 91.8% of patients developed anemia, with 138 (53.9%) experiencingmoderate anemia and 19 (7.4%) encountering severe anemia. Furthermore, about 75 (29.3%)patients had thrombocytosis, while 34 (13.3%) had thrombocytopenia. The most common sign andsymptoms developed were Fatigue, abdominal pain, splenomegaly, and weight loss. Conclusion: This study revealed a significant prevalence of hyperleukocytosis and anemia among CML patients during their initial presentation. Fatigue, abdominal pain, splenomegaly, and weightloss emerged as the most commonly observed signs and symptoms in CML patients. | |
| dc.identifier.uri | https://etd.aau.edu.et/handle/123456789/6678 | |
| dc.language.iso | en_US | |
| dc.publisher | Addis Ababa University | |
| dc.subject | BCR-ABL newly confirmed chronic myeloid leukemia hematological profile Clinical Profile TASH | |
| dc.title | Hematological and Clinical Profile of BCR-ABL Confirmed Chronic Myeloid Leukemia Patients at Presentation in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia | |
| dc.type | Thesis |